-- Poster 442--A Phase 3 Comparative Study of the Safety & Efficacy of
Cethromycin 150 mg QD and Penicillin V 500 mg TID for the Treatment of
-- Poster 443--Assessment of the Pharmacokinetic Interaction between
Cethromycin and Rifampin
-- Poster 444--Assessment of the Pharmacokinetic Interaction between
Cethromycin and Ketoconazole
-- Poster 450--Single-Dose Bioavailability of Cethromycin Granules for
Suspension Formulation in Healthy Adult Subjects
Advanced Life Sciences is developing cethromycin, a novel once-a-day antibiotic in response to the emerging bacterial resistance observed in the treatment of community acquired pneumonia (CAP). Cethromycin has been tested in approximately 5,000 human subjects during clinical trials.
The Company conducted two, pivotal Phase III clinical trials of cethromycin for the treatment of mild-to-moderate CAP. In June of 2007, Advanced Life Sciences released positive results from the first of these two trials, Trial CL-06, which showed that cethromycin met primary and secondary clinical endpoints. The Company expects data from the second trial, CL-05 to be reported in the Fall. The Company believes that cethromycin, if approved, would build upon the growing market opportunity in the antibiotic marketplace and address the critical need for antibiotics that overcome bacterial resistance.
About Advanced Life Sciences
Advanced Life Sciences is a biopharmaceutical company engaged in the
discovery, development and commercialization of novel drugs in the
therapeutic areas of infection, cancer and inflammation. The Company's lead
candidate, cethromycin, is a novel once-a-day antibiotic in late-stage
clinical development for the treatment of respiratory tract infections. For
more information, please visit us on the web at
|SOURCE Advanced Life Sciences Holdings, Inc.|
Copyright©2007 PR Newswire.
All rights reserved